Paper41002563
Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis.
Cao D and 1 other. Curr Oncol, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis. Papers, record 41002563. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41002563
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Liver Neoplasms | Major topic |
| Tumor Microenvironment | Major topic |
| Humans |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2023ZD0501600 | Noncommunicable Chronic Diseases-National Science and Technology Major Project | PubMed |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36892833 | Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. | JAMA Oncol | 2023 | https://conductscience.org/library/papers/36892833 | PubMed |
| 2 | 31590148 | Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer. | J Natl Compr Canc Netw | 2019 | https://conductscience.org/library/papers/31590148 | PubMed |
| 3 | 23177514 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. | Lancet | 2013 | https://conductscience.org/library/papers/23177514 | PubMed |
| 4 | 35705369 | Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. | Gut | 2023 | https://conductscience.org/library/papers/35705369 | PubMed |
| 5 | 38865678 | Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38865678 | PubMed |
| 6 | 38833658 | Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38833658 | PubMed |
| 7 | 18421054 | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18421054 | PubMed |
| 8 | 35246503 | Colorectal liver metastasis: molecular mechanism and interventional therapy. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35246503 | PubMed |
| 9 | 37480104 | Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37480104 | PubMed |
| 10 | 35427471 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35427471 | PubMed |
| 11 | 35636444 | Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35636444 | PubMed |
| 12 | 38024475 | Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). | EClinicalMedicine | 2023 | https://conductscience.org/library/papers/38024475 | PubMed |
| 13 | 32849517 | Myeloid-Derived Suppressor Cells in Colorectal Cancer. | Front Immunol | 2020 | https://conductscience.org/library/papers/32849517 | PubMed |
| 14 | 24120480 | Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. | Lancet Oncol | 2013 | https://conductscience.org/library/papers/24120480 | PubMed |
| 15 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 16 | 28192899 | Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry. | J Pathol Transl Med | 2017 | https://conductscience.org/library/papers/28192899 | PubMed |
| 17 | 32379280 | Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32379280 | PubMed |
| 18 | 29754777 | International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. | Lancet | 2018 | https://conductscience.org/library/papers/29754777 | PubMed |
| 19 | 36707233 | Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. | Gut | 2023 | https://conductscience.org/library/papers/36707233 | PubMed |
| 20 | 34725151 | Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34725151 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42983433 | Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42983433 | PubMed |
| 42980805 | Mast cell-derived SPP1 promotes colorectal cancer liver metastasis by suppressing BTG1-mediated JUN degradation. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/42980805 | PubMed |
| 42723950 | Longitudinal analysis of genomic and immune differences between primary and metastatic nasopharyngeal carcinoma for precision oncology. | Front Oncol | 2026 | https://conductscience.org/library/papers/42723950 | PubMed |
| 42640498 | Noninvasive molecular imaging signatures of histopathological growth patterns in colorectal cancer liver metastases. | Clin Exp Metastasis | 2026 | https://conductscience.org/library/papers/42640498 | PubMed |
| 42558893 | Targeting molecular residual disease and immune escape in colorectal cancer recurrence: biomarker-guided immunotherapy and cell therapies. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42558893 | PubMed |
| 42358994 | Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42358994 | PubMed |
| 42253947 | Organ-specific pre-metastatic and metastatic niches in colorectal cancer: "discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis". | Front Immunol | 2026 | https://conductscience.org/library/papers/42253947 | PubMed |
| 41832460 | The prognostic value of immunoscore in colorectal cancer liver metastases: a meta-analysis reveals the superiority of metastatic over primary tumor profiling. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41832460 | PubMed |
| 41749820 | Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749820 | PubMed |
| 41228231 | Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228231 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41002563
GET https://conductscience.org/api/papers/v1/41002563/references?page=2